Gerald L. Chan

Co-founder, Morningside Group

Gerald Chan co-founded Morningside in 1986. As a privately-held investment group, Morningside is active in both private equity and venture capital investments in North America, Europe and Asia. The group began its China investments in 1992 and remains active in China's internet, education and life science sectors.

Dr. Chan is currently a board member of the Hang Lung Group, a large real estate company listed on the Hong Kong Stock Exchange. He serves on the boards of several biotechnology companies including Critical Biologics, CellCentric., Green Biologics, Stealth Peptides, Matrivax, Advanced Cell Diagnostics, and Vaccine Technologies Inc. Dr. Chan is a trustee of Fudan University in Shanghai and sits on the advisory boards of the Johns Hopkins University - Nanjing University Center for Chinese and American Studies, The Institute of Mathematical Science of the Chinese University of Hong Kong, the International Society for Stem Cell Research, Harvard University China Advisory Group, and the Physical Sciences Visiting Committee of UCLA. Dr. Chan is a director of the Morningside Foundation which endowed the Morningside College at the Chinese University of Hong Kong. With Nobel laureate James Mirrlees as the founding Master, the College will have its first intake of students in the fall of 2010.

Dr. Chan received his BS and MS degrees in Engineering from UCLA, a Master of Science degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana Farber Cancer Institute, Harvard Medical School where he was a fellow of the Leukemia Society of America.